Reporter Park Dong-young, Bio Spectator
Signed a technology transfer contract for high-efficiency cell culture technology platform’MLSC’
Medipost announced on the 23rd that it has signed a technology transfer contract with LG Chem for the high-efficiency cell culture technology platform’MLSC’.
Medipost grants LG Chem a license to develop and commercialize products using related technologies such as MLSC, and LG Chem will expand the development of a gene cell therapy pipeline by incorporating its own gene technology.
Under the contract, Medipost receives a down payment with no return condition. In the future, when LG Chem’s global clinical development progress and commercialization are performed, milestones will be sequentially received according to sales, and additional royalties will be received according to net sales. LG Chem owns the worldwide exclusive development and commercialization rights of gene cell therapy products discovered through joint research by both companies.
Yang Yun-seon, CEO of Medipost, said, “The active collaboration between the two companies allowed us to discover the best candidates for gene cell therapy within synergy.” “Because this technology transfer is the transfer of the license to open platform technology for cell culture, our own pipeline development In addition, it is possible to transfer additional technology to other companies.”
Ji-woong Sohn, head of the life science business division of LG Chem, said, “We have confirmed the possibility of development as an innovative gene cell therapy product through two years of joint research with Medipost, which has the best capability in Korea, in the field of stem cells. “We plan to launch first-in-class products that can fundamentally treat diseases with many medical unmet needs in the global market.”